Clinical Trials in Philadelphia

Showing 13381-13400 of 20,904 trials

Endophenotype for Alcohol Misuse in Healthy Minority Populations

NCT00256451

The purpose of the study is to understand the relationship between what an individual inherited from their family (genetics), how they respond and feel after drinking alcohol, and how they respond to pre-treatment with naltrexone, a medication that blocks some of the effects of alcohol and is approved for the treatment of alcoholism. The investigators are conducting this study on those of African descent because there is almost no research focused on this group and the association with genetics. The investigators seek to enroll 40 people in the study. Participation will consist of 4 different alcohol challenge sessions in a cross over design. Each session will be separated by at least 10 days. In total, there will be four challenge sessions.

Healthy

University of Pennsylvania43 participantsStarted Nov 2005

Philadelphia, Pennsylvania, United States

COMPLETEDPhase 2/3< 1 mile

A Study to Evaluate the Effect of Dapagliflozin With and Without Saxagliptin on Albuminuria, and to Investigate the Effect of Dapagliflozin and Saxagliptin on HbA1c in Patients With Type 2 Diabetes and CKD

NCT02547935

The purpose of this clinical research study is to determine whether dapagliflozin alone or in combination with saxagliptin can decrease albuminuria and improve glycemic control in patients with Type 2 diabetes, albuminuria and renal impairment (CKD). The study is planned to randomize a total of 450 patients (150 patients per treatment arm)

Type 2 Diabetes Mellitus, CKD and Albuminuria

AstraZeneca459 participantsStarted Sep 2015

Peoria, Arizona, United States • Chula Vista, California, United States • Concord, California, United States +109 more locations

Endophenotype for Alcohol Misuse in Healthy Minority Populations

A Study to Evaluate the Effect of Dapagliflozin With and Without Saxagliptin on Albuminuria, and to Investigate the Effect of Dapagliflozin and Saxagliptin on HbA1c in Patients With Type 2 Diabetes and CKD

Find Trials by Condition in Philadelphia

A Safety Extension Study to Evaluate the Safety and Tolerability of Benralizumab (MEDI-563) in Asthmatic Adults and Adolescents on Inhaled Corticosteroid Plus LABA

Expanded Access /Compassionate Use Protocol For Relapsed Or Refractory CD33 Positive AML Patients In The USA Without Access To Comparable Or Alternative Therapy

Observational Study of Kibow Biotics in Dialysis Patients

A Study of Disease Progression in Participants With Geographic Atrophy Secondary to Age-Related Macular Degeneration

MIS ReFRESH: Robotic vs. Freehand Minimally Invasive Spinal Surgeries

Long-term Safety and Tolerability of Cariprazine as an Adjunctive Treatment to Antidepressant Therapy in Patients With Major Depressive Disorder

Acupuncture for Promotion of Timely Delivery

Evaluation of Two Regimens, With Healthy Male and Female Babies, Ages 3-6 Months Old, Using Various Assessments.

BOTOX® Open-Label Treatment in Pediatric Lower Limb Spasticity

Efficacy and Safety of Etelcalcetide (AMG 416) in the Treatment of Secondary Hyperparathyroidism (SHPT) in Patients With Chronic Kidney Disease (CKD) on Hemodialysis

A Dose-Range Finding Study for ALX-0061 Combination Therapy in Subjects With Rheumatoid Arthritis

Expanded Noninvasive Genomic Medical Assessment: The Enigma Study

A Study of the Effect of XmAb®5871 in Patients With Systemic Lupus Erythematosus

A Study of ERY974 in Patient With Advanced Solid Tumors

A Phase IIb Study for ALX-0061 Monotherapy in Subjects With Rheumatoid Arthritis

Does Use of Rapid Response EEG Impact Clinical Decision Making

An Effectiveness and Safety Study of Inhaled JNJ 49095397 (RV568) in Patients With Moderate to Severe Chronic Obstructive Pulmonary Disease

A Study to Assess All-Cause Mortality and Cardiovascular Morbidity in Participants With Chronic Kidney Disease (CKD) on Dialysis and Those Not on Renal Replacement Therapy Receiving Methoxy Polyethylene Glycol-Epoetin Beta (Mircera) or Reference Erythropoietin Stimulating Agents (ESAs)